Skip to main content
SpringerLink
Log in

Safety information regarding the risk of severe and sometimes fatal hypocalcaemia with denosumab [XGEVA]

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Amgen Canada.XGEVA (denosumab) - Risk of severe symptomatic hypocalcemia, including fatal cases. Internet Document: [2 pages], 28 May 2012. Available from: URL: http://www.hc-sc.gc.ca

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Safety information regarding the risk of severe and sometimes fatal hypocalcaemia with denosumab [XGEVA]. React. Wkly. 1416, 5 (2012). https://doi.org/10.2165/00128415-201214160-00014

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214160-00014

Keywords

Search

Navigation